American Journal of Ophthalmology
Volume 145, Issue 4 , Pages 598-603.e1, April 2008

Role of Optic Nerve Imaging in Glaucoma Clinical Practice and Clinical Trials

  • David S. Greenfield

      Affiliations

    • Department of Ophthalmology, University of Miami Miller School of Medicine, Bascom Palmer Eye Institute, Palm Beach Gardens, Florida
    • Corresponding Author InformationInquiries to David S. Greenfield, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, 7101 Fairway Drive, Palm Beach Gardens, FL 33418
  • ,
  • Robert N. Weinreb

      Affiliations

    • Hamilton Glaucoma Center, University of California, San Diego, La Jolla, California.

Accepted 13 December 2007. published online 28 January 2008.

Purpose

To provide an update on the role of optic nerve and peripapillary retinal nerve fiber layer imaging in glaucoma clinical practice and clinical trials.

Design

Perspective.

Methods

Review of recent literature and authors’ clinical and laboratory studies.

Results

Imaging technologies such as confocal scanning laser ophthalmoscopy, scanning laser polarimetry, and optical coherence tomography provide objective and quantitative measurements that are highly reproducible and show very good agreement with clinical estimates of optic nerve head structure and visual function. Structural assessments provided by imaging complement optic disk photography in clinical care and have the potential to identify relevant structural efficacy endpoints in glaucoma randomized clinical trials. As with other technologies, imaging may produce false identification of glaucoma and its progression; thus, clinicians should not make management decisions based solely on the results of one single test or technology.

Conclusions

Although optic disk stereophotography represents the standard for documentation of glaucomatous structural damage in practice and research trials, advances in computerized imaging technology provide useful measures that assist the clinician in glaucoma diagnosis and monitoring and offer considerable opportunity for use as efficacy endpoints in clinical trials.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0002-9394(07)01071-9

doi:10.1016/j.ajo.2007.12.018

American Journal of Ophthalmology
Volume 145, Issue 4 , Pages 598-603.e1, April 2008